Hypoxia-related diseases like ischemic heart disease, cancer, and stroke have long been a major focus for drug developers. ADO (2-aminoethanethiol dioxygenase) is a key player in the oxygen-sensing pathway—it oxidizes N-terminal cysteine residues, which in turn affects protein stability. But for years, no one had a clear picture of how ADO binds its substrates, and that knowledge gap has held back rational inhibitor design. A recent paper in Nature Communications by Jiramongkol and colleagues can change. They used mRNA display (RaPID) to find cyclic peptide inhibitors of ADO, and then took the clever step of using one of those cyclic peptides as a scaffold to solve the crystal structure of ADO bound to a substrate analogue. This article walks through their strategy and looks at how specialized cyclic peptide characterization and quality control services can help move this kind of high-quality research from the bench toward broader applications.
Hypoxic adaptation is central to the pathology of many diseases. ADO, a member of the N-terminal cysteine oxidase (NCO) family, regulates the stability of hypoxia-related proteins through the N-degron pathway and has emerged as a potential therapeutic target. Yet the lack of clarity on its substrate binding mechanism has hindered chemical probe and drug discovery.
ADO catalyzes the oxidation of N-terminal cysteine, the first step in a protein degradation signal. Under normoxia, ADO continuously marks substrate proteins for degradation; under hypoxia, ADO activity drops, allowing substrate proteins to stabilize. Substrates such as RGS4/5 and IL32 are linked to cardiovascular function and tumor progression, making ADO a promising target for cancer and ischemic disease. However, the molecular details of ADO substrate binding have remained unresolved, mainly due to low substrate affinity and rapid turnover, which have prevented co-crystallization.
Cyclic peptides, with their conformational constraint, metabolic stability, and high affinity, are well suited for targeting protein-protein interactions or enzyme active sites. Traditional discovery methods such as phage display are limited to natural amino acids, whereas mRNA display with non-standard amino acids (RaPID) overcomes this limitation. Nevertheless, after discovering a cyclic peptide, researchers still face a practical question: how to confirm structural integrity, cyclization site, and batch consistency? These characterization efforts directly determine the reliability of downstream structural and mechanistic studies.
The work by Jiramongkol and colleagues proceeded in three steps: first, RaPID screening to obtain high-affinity cyclic peptide inhibitors; second, solving the inhibitor-bound structure and identifying a key catalytic residue; third, using the cyclic peptide as a scaffold to graft substrate moieties and successfully obtaining substrate-analogue-bound crystal structures. Each step demonstrates a clever application of cyclic peptides in chemical biology.
The researchers constructed a cyclic peptide library containing over 1012 members and, after six rounds of selection, enriched eight major cyclic peptides (CP1-8). SPR binding experiments showed that CP1, 5, 6, and 8 had equilibrium dissociation constants (KD) between 5 and 66 nM, with CP8 being the tightest binder (KD = 5 nM). Enzyme inhibition assays confirmed that CP1, 5, 6, and 8 had IC50 values in the single-digit micromolar range.
The identification and characterisation of cyclic peptide (CP) inhibitors of ADO1,5
To understand why CP6 exhibited non-competitive inhibition, the team solved the crystal structure of cobalt-substituted ADO in complex with CP6 at 1.74 Å resolution. CP6 adopts an antiparallel β-sheet conformation, lies across the DSBH core of ADO, and blocks the active site entrance. Structural analysis revealed that phenylalanine 6 (F6) in CP6 influences the catalytic residue D206 through a hydrogen bond network, pulling it away from the metal center.
A crystal structure of ADO in complex with CP6 elucidates its mode of inhibition and highlights a putative catalytic residue2,5
Because obtaining an ADO-substrate co-crystal directly proved extremely difficult, the team cleverly used CP6 as a molecular scaffold. They selected CP6-L8, a residue that extends into the active site but does not contribute to binding, replaced it with lysine or diaminopropionic acid (Dap) bearing a side-chain amine, and then coupled cysteine or serine (serine serves as a substrate analogue). This design allowed the pseudo-N-terminus to reach into the active site and contact the metal.
Employing CP6 as a scaffold to graft substrate moieties3,5
Ultimately, the team obtained the crystal structure of CP6-L8K-Ser in complex with ADO at 1.60 Å resolution and the structure of CP6-L8d-Gly-Ser in complex with ADO at 1.74 Å resolution. In both structures, the pseudo-N-terminal serine coordinates the metal center in a bidentate manner (both hydroxyl and amino groups ligated), leaving a single water molecule in the trans position, which is considered the oxygen binding and activation site. In addition, F101 forms a π-stacking interaction with the substrate amide, Y212 forms a hydrogen bond with the hydroxyl group, and D206 forms a hydrogen bond with the amino group.
A crystal structure of ADO in complex with CP6-L8K-Ser reveals key substrate binding interactions4,5
The work by Jiramongkol and colleagues demonstrates the strong potential of cyclic peptides in chemical biology. However, for most laboratories or companies working on cyclic peptides, reproducing such high-level results often encounters several practical bottlenecks.
Making cyclic peptides for binding and activity assays comes with several practical hurdles.
These challenges highlight the importance of reliable cyclic peptide characterization. High-quality structural data depends on pure, uniform samples, which in practice require solid analytical support—such as HPLC or UPLC for purity, LC-MS/MS for mass and cyclization confirmation, and amino acid analysis when needed. As projects progress beyond early discovery, maintaining batch-to-batch consistency also becomes increasingly critical.
Based on the analysis above, it is clear that cyclic peptide research has a critical need for characterization and quality control. Creative Peptides offers targeted cyclic peptide characterization services to help research teams verify material quality, compare production batches, and prepare qualified peptide candidates for downstream development.
We use a range of analytical tools adapted to the project stage to ensure that the identity and purity of cyclic peptide samples meet research objectives:
Cyclic peptide projects often involve multiple synthesis batches: early screening, structural optimization, pharmacological evaluation, and potential process scale-up. Inconsistent quality between batches can lead to non-comparable data and unreliable conclusions. We offer batch comparability analysis services, using standardized analytical methods and documentation to help you track purity, impurity profiles, and critical quality attributes across batches. These documentation packages can support enterprise vendor management and technology transfer needs, allowing your cyclic peptide candidates to move smoothly from discovery to development.
From mRNA display screening through to crystal structure determination, each stage relies on cyclic peptide samples with high purity and well-defined composition. This underscores that progress in cyclic peptide research depends not only on identifying active sequences, but also on confirming their identity and quality with confidence.
Creative Peptides provides flexible and professional characterization and quality control support tailored to cyclic peptide projects. Whether at the screening stage or preparing documentation for batch consistency, technical assistance is available to support project needs.
Ready to move forward?
Contact us today to get started and receive a customized solution for your project.
References
